Evidence map›Paper›PMID 32963252›Full record

ArticleNature communications2020

Cryo-EM structure of the varicella-zoster virus A-capsid.

Junqing Sun, Congcong Liu, Ruchao Peng, Fu-Kun Zhang, Zhou Tong, Sheng Liu, Yi Shi, Zhennan Zhao, Wen-Bo Zeng, George Fu Gao and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Bee products as alternatives in the treatment of viral infections.Journal of the science of food and agriculture · 2026
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Junqing Sun *Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China.
Congcong Liu *Cryo-EM Centre, Southern University of Science and Technology, Shenzhen, 515055, China.ORCID http://orcid.org/0000-0002-8675-9100
Ruchao Peng *CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China.ORCID http://orcid.org/0000-0002-2741-6212
Fu-Kun Zhang *Changchun Keygen Biological Products Co. Ltd., Changchun, 130000, China.
Zhou Tong *Shanxi Academy of Advanced Research and Innovation, Taiyuan, 030032, China.
Sheng LiuCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China.
Yi ShiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China.ORCID http://orcid.org/0000-0002-3053-2687
Zhennan ZhaoCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China.
Wen-Bo ZengState Key Laboratory of Virology, CAS Center for Excellence in Brain Science and Intelligence Technology, Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.ORCID http://orcid.org/0000-0002-1334-2726
George Fu GaoCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China.ORCID http://orcid.org/0000-0002-3869-615X
Hong-Jie ShenChangchun Keygen Biological Products Co. Ltd., Changchun, 130000, China.
Xiaoming YangChina National Pharmaceutical Group Corporation, Beijing, 100029, China. yangxiaoming@sinopharm.com.ORCID http://orcid.org/0000-0002-2598-4355
Minhua LuoUniversity of Chinese Academy of Sciences, Beijing, 100049, China. luomh@wh.iov.cn.ORCID http://orcid.org/0000-0001-9352-0643
Jianxun QiCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. jxqi@im.ac.cn.
Peiyi WangCryo-EM Centre, Southern University of Science and Technology, Shenzhen, 515055, China. wangpy@sustech.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Varicella-zoster virus (VZV), a member of the Alphaherpesvirinae subfamily, causes severe diseases in humans of all ages. The viral capsids play critical roles in herpesvirus infection, making them potential antiviral targets. Here, we present the 3.7-Å-resolution structure of the VZV A-capsid and define the molecular determinants underpinning the assembly of this complicated viral machinery. Overall, the VZV capsid has a similar architecture to that of other known herpesviruses. The major capsid protein (MCP) assembles into pentons and hexons, forming extensive intra- and inter-capsomer interaction networks that are further secured by the small capsid protein (SCP) and the heterotriplex. The structure reveals a pocket beneath the floor of MCP that could potentially be targeted by antiviral inhibitors. In addition, we identified two alphaherpesvirus-specific structural features in SCP and Tri1 proteins. These observations highlight the divergence of different herpesviruses and provide an important basis for developing antiviral drugs.

Indexed as

CapsidCapsid ProteinsCell LineCryoelectron MicroscopyHerpesvirus 3, HumanHumansModels, MolecularProtein ConformationProtein DomainsCapsid Proteins

Identifiers

PMID32963252
PMCPMC7508878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.